Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA Wary Of Large Simple Safety Trials, Tells FDA Not To Create Phase III+

Executive Summary

Large simple safety studies should not become a routine pre-approval requirement, the Pharmaceutical Research & Manufacturers of America suggested during FDA's risk management public workshop April 9

You may also be interested in...



Adverse Event Reporting Requirements Can Be “Flexible,” FDA Says

Some FDA review divisions are reaching agreements that allow drug sponsors to submit less adverse event data to the agency

Adverse Event Reporting Requirements Can Be “Flexible,” FDA Says

Some FDA review divisions are reaching agreements that allow drug sponsors to submit less adverse event data to the agency

Dose Ranging Study In Phase III Could Bolster Rx Safety Profile, Temple Says

Evaluating a range of doses in Phase III clinical trials could bolster the safety profile for an investigational new agent, FDA Office of Medical Policy Director Robert Temple, MD, said April 9

UsernamePublicRestriction

Register

PS041623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel